anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aortic stenosis (AS) is the most common valvular pathology in the elderly population, and there is an anticipated increase in prevalence and associated costs for treating this condition in the future. In a non-negligible percentage of cases (approximately 15%), another pathology is associated, namely cardiac amyloidosis, especially in the wild-type ATTR form. Patients with both pathologies (AS+ATTR) have a worse prognosis compared to those with AS alone. Based on the available data up to now, ATTR-associated amyloidotic cardiomyopathy does not appear to significantly influence the immediate outcome of TAVI or short-term outcomes. However, among patients with amyloidosis, there is an increased frequency of heart failure in subsequent follow-ups. The mechanism behind this dual pathology remains unclear. Epidemiological similarities (advanced age) alone do not explain the association. It is possible that there is a direct causal link between amyloidosis and aortic stenosis (amyloidosis as a co-cause or contributing factor to valvular stenosis), or that the elevated intramyocardial strain due to degenerative valvular stenosis promotes amyloidogenesis and myocardial infiltration. Understanding the extent of valvular calcifications in individual cases would provide better insights into the pathogenesis of this dual pathology. There are also diagnostic implications. Amyloidosis could potentially complicate the accurate classification of the severity of aortic pathology. For example, patients with AS+ATTR often exhibit a "low-flow low-gradient" paradoxical hemodynamic profile. In these cases, estimating the valve area with an echocardiogram is challenging, and evaluating the valvular calcium score through CT assumes an important diagnostic role. Preliminary studies suggest that, for the same degree of stenosis severity, there may be a lower quantity of calcium in the valves of patients with AS+ATTR compared to those with AS alone. Preliminary studies suggest that, for the same degree of stenosis severity, there may be a lower quantity of calcium in the valves of patients with AS+ATTR compared to those with AS alone. In a 1:1 propensity matching of over 300 patients (mostly without aortic stenosis), those with amyloidosis had lower aortic valvular calcium scores (p\<0.01). In a small series of 13 cases with AS+ATTR, 12 had aortic valvular calcium scores below the severity cut-offs recommended by the guidelines. If confirmed, traditionally used calcium score cut-offs may be inadequate, with significant implications for treatment selection and therefore prognosis.
Video assisted thoracic surgery (VATS) has recently been evaluated as the standard surgical procedure for lung surgery. The advantages of VATS procedures compared with open thoracotomy are rapid recovery, short hospital stay and low complication risk. Although VATS is less painful than thoracotomy, patients may feel severe pain during the first hours at postoperative period. Analgesia management is very important for these patients in postoperative period since insufficient analgesia can cause pulmonary complications such as atelectasis, pneumonia and increased oxygen consumption.

The ultrasound (US) guided erector spina plane (ESP) block is a novel interfacial plan block defined by Forero et al. at 2016. ESP block provides thoracic analgesia at T5 level and abdominal analgesia at T7-9 level. The ESP block contains a local anesthetic injection into the deep fascia of erector spinae. This area is away from the pleural and neurological structures and thus minimizes the risk of complications due to injury. Visualization of sonoanatomy with US is easy, and the spread of local anesthesic agents can be easily seen under the erector spinae muscle. Thus, analgesia occurs in several dermatomes with cephalad-caudad way. Cadaveric studies have shown that the injection spreads to the ventral and dorsal roots of the spinal nerves and creates sensory blockade in both posterior and anterolateral thorax. In the literature, it has been reported that ESP block provides effective analgesia after open heart surgery, breast surgery and ventral hernia repair in randomized controlled studies about ESP block efficiency for postoperative analgesia management. In some case series and case reports it has been reported that ESP block provides effective analgesia after thoracotomy and VATS. Furthermore, it has been reported that it provides effective analgesia in chronic and persistant pain syndromes of thorax.

US-guided serratus anterior plane (SAP) block is an interfascial plane block and was described by Blanco in 2013. A local anesthetic solution is performed into the fascial plane of serratus anterior muscle. It is easy to perform and has low complication rate because it is far away from the important neurological and vascular structures. The serratus anterior muscle may be seen easily with US guidance in the mid-axillary line. It provides effective analgesia in anterior, posterior and lateral dermatomes of thorax. It has been reported that SAP block provides effective postoperative pain management following thoracotomy, breast surgery and VATS. There is no clinical randomized study evaluating the efficacy of ESP block and SAP block following VATS in the literature.

The aim of this study is to compare US-guided ESP block and SAP block for postoperative analgesia management after VATS. The primary aim is to compare perioperative and postoperative opioid consumption and the secondary aim is to evaluate postoperative pain scores (VAS), adverse effects related with opioids (allergic reaction, nausea, vomiting) and complications due to blocks (pneumothorax, hematoma).
FIELD: medicine.SUBSTANCE: group of inventions refers to postpartum haemorrhage treatment. Orally disintegrating solid pharmaceutical dosage unit for treating postpartum haemorrhage has weight ranging from 50 to 500 mg and consists of 1–100 wt. % particles, consisting of 0.01–10 wt. % of controlling the generic activity of oxytocin, 5–70 wt. % of buffer agent, 20–94 wt. % of branched glucan and 0–70 wt. % of other pharmaceutically acceptable ingredients; and 0–99 wt. % of one or more pharmaceutically acceptable excipients; wherein said solid dosing unit contains at least 5 mcg of the substance controlling the substance and has a buffer pH in range of 3.5–5.7. Also disclosed is the use of oxytocin for preparing a dosage unit for treating postpartum haemorrhage and a method for preparing a solid dosage unit.EFFECT: group of inventions provides a stable dosing unit for treating postpartum haemorrhage.10 cl, 8 tbl, 5 ex
PCT No. PCT/US95/13715 Sec. 371 Date Jun. 27, 1997 Sec. 102(e) Date Jun. 27, 1997 PCT Filed Apr. 24, 1995 PCT Pub. No. WO96/13286 PCT Pub. Date May 9, 1996Intraocular devices which are capable of sustained release of a cell proliferation modulating agent, together with methods for their preparation and use, are provided. The proliferation modulating agent is associated either covalently or non-covalently with the material from which the intraocular device is prepared, generally a biologically inert polymer which is physiologically compatible with ocular tissue. The intraocular devices are implanted in the tissue, and the drug is released from the intraocular device such that the drug is substantially retained within the implant region. The device may be used to inhibit cellular proliferation around the implant. The device can be provided as a sterile kit, preferably in a form suitable for immediate use.
Quality improvement (Ql) methods are a cornerstone of business and healthcare management throughout the United States yet there have been few studies of Ql interventions in addiction treatment settings. The proposed study tests the effectiveness of one Ql system - Patient Feedback (PF) - at increasing outpatient group therapy attendance and self-reported abstinence. The feasibility and acceptability of PF was established in a six-site study conducted within the National Drug Abuse Treatment Clinical Trials Network. In the proposed study, 32 community-based outpatient treatment programs with approximately 250 clinicians will be randomly assigned to PF, or usual clinic practices. In the PF condition, every week fro 12 weeks clinic patients are invited to complete a 12-item, self-administered survey in which they rate therapeutic alliance and treatment satisfaction, and report past week substance use. These anonymous surveys are faxed by clinic staff to a University of Pennsylvania data center where a custom software application converts the surveys into feedback reports and posts them to a password protected website. Clinicians can access their caseload feedback reports and aggregated reports for the whole clinic; supervisors can only access the aggregated clinic reports. On a monthly basis staff meet as a team to review the feedback reports and develop Ql plans intended to yield improvements in select Ql indicators. The PF website and the monthly PF e-newsletter provide social recognition, clinical resources, and a virtual community for participating clinicians. After 12 weeks, participants in both conditions complete follow-up measures and then both groups are given open access to PF for 12 additional months. During "sustainability phase" staff usage of the PF website is monitored. Alternate versions of the PF Survey are introduced during the sustainability study, including one that monitors HIV risk behavior. The rapid processing of surveys enables near real time feedback to clinic staff. Organizations may share their feedback reports with funding sources, regulatory agencies, policy makers, and other stakeholders. This centralized, semi-automated feedback system eases fulfillment of accreditation requirements and as such, reduces the cost of clinic operations.
This will be a randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, PK, and PD of oral TMP-301, given concurrently with cocaine. The study will consist of 4 phases: Screening, Baseline, Treatment, and Follow-up. The Screening Phase will be completed as an outpatient visit within 24 days of the Baseline Phase and will consist of a standard medical screen. Within 24 days of a standard medical screening, eligible participants will return to the clinical site as inpatients to complete the Baseline Phase. All participants will remain in-clinic for the duration of the 7-day Treatment Phase. Following confirmation of eligibility, participants will be randomized to one of two treatment groups, either TMP-301 or. A safety follow-up visit will be conducted on Day 23.
Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
Although the burden of cancer is high among individuals of all ethnicities, ethnic differences in cancer incidence and mortality exist. African-Americans experience a higher incidence of certain cancers compared with the White population, with mortality rates at least 40% higher than other populations. Obesity, high fat, and low fruit (F) and vegetable (V) intakes increase cancer risks. Cancers may develop over a long period of time, with some possibly initiating in childhood; therefore, promoting FV and preventing excess weight gain during childhood could be cancer protective. Families influence children's dietary behaviors by direct modeling of dietary behaviors, parenting skills around food, and controlling the home food environment. However, few intervention studies have focused on family influences on dietary behaviors, particularly among ethnic minority groups which may differ in cultural and other aspects of family functioning. Unfortunately, low participation rates for community-based family interventions suggest that alternate intervention delivery systems be investigated. The internet provides family access within the convenience of the home. In a previous R21 application, the Principal Investigator developed an eight-session interactive web-based program promoting a healthy home food environment for African-American families with 9-12 year old daughters (Family Eats). Family Eats was evaluated for feasibility and changes in mediating variables were obtained. This proposal will test the efficacy of the Family Eats web program to improve FV and dietary fat behavior and weight outcomes among 320 AA families with 8-12 year old children. This important study will pioneer a new channel for behavior change intervention with African-American families and holds the promise of reaching large numbers of children and their families, enabling all to adopt healthy eating behaviors and achieve energy balance and reduce cancer risks.
Rheumatoid arthritis is always a research hotspot in the field of rheumatology, and till now, no ideal drug has been developed. The disease has a high rate of disability, thereby bringing numerous patients agony and economic burden. The joint ease capsule of the invention has the effects of expelling pathogenic cold from channel, expelling wind, removing dampness, regulating qi and blood, regulating yin and yang, promoting blood circulation, dispelling blood stasis, and strengthening muscles and bones; and has distinct therapeutic effect on rheumatoid arthritis with clinic cure rate up to 72.86%. The therapeutic action mechanism of the inventive capsule includes that: (1) bidirectionally regulating immunity, inhibiting the generation of autologous antibody (i.e. rheumatoid factor), and inhibiting the damage of inflammatory immunological reaction to articular synovial membrane and articular cartilage, so as to promote the rehabilitation of the articular synovial membrane and the articular cartilage with pathological changes; (2) inhibiting the formation of interleukin-6 and tumor necrosis factors, so as to stop the irritation thereof to the articular synovial membrane and the articular cartilage; and (3) increasing the activity of superoxide dismutase and peroxidase, reducing the generation of free radicals, so as to prevent the damage thereof to the synovial membrane and the articular cartilage, eliminate the rigidity and deformity of a joint with pathological changes and promote function rehabilitation of the joint with pathological changes. Therefore, the joint ease capsule is an effective new drug for treating rheumatoid arthritis, and at the same time, has a distinct therapeutic effect on the prolapse of intervertebral disc.
The invention discloses cleansing milk. The cleansing milk comprises a surfactant, a humectant, a nutrient, an emollient, an essence and a bacteriacide, and is characterized in that the bacteriacide is bacillus subtilis (CGMCC 6012) fermentation liquor extract. By the cleansing mile, the dirt on the skin can be removed; moreover, the cleansing milk has good sterilization and disinfection functions; and particularly, the invention is characterized in that the cleansing milk can kill methicillin-resistant staphylococcus aureus. The bacteriacide which is added into the cleansing milk is produced by using fermentation raw materials with low cost and applying a modern biotechnology, the process is simple, and the cost is low. Therefore, the cleansing milk has high bactericidal power and technical content, and is safe and cheap. In addition, the bacteriacide which is added into the cleansing milk and is obtained by processing pure natural fermentation raw materials by the modern biotechnology also has an anticorrosive function, and has the characteristics of safety and high efficiency.
INTRODUCTION: Conjunctivitis is a highly prevalent ocular disease that flares up every year. The humidity and high temperature favour the causative agents responsible for the epidemic. Acute infective conjunctivitis may be either viral or bacterial, a distinct type of condition with unique clinical features and treatment approaches. The aim of the study was to find out the prevalence of acute conjunctivitis among patients visiting the outpatient Department of Ophthalmology in a tertiary care centre.
METHODS: This descriptive cross-sectional study was conducted among the patients visiting the outpatient Department of Ophthalmology. Data of 30 August 2023 to 30 September 2023 was collected between 21 November 2023 to 24 November 2023. All patients presenting in the Ophthalmology Department having complete hospital record were included in the study. Patients having missing data on the medical records of the hospital were excluded. A convenience sampling method was used. The point estimate was calculated at a 95% Confidence Interval.
RESULTS: Among 5,507 patients, acute conjunctivitis was seen in 1240 (22.52%) (21.42-23.62, 95% Confidence Interval). The majority were male 732 (59.03%) and adults 760 (61.29%) with a mean age of 32.56±18.74 years.
CONCLUSIONS: The prevalence of conjunctivitis among patients visiting the outpatient Department of Opthalmology was found to be higher than other studies done in similar settings.
KEYWORDS: conjunctivitis; disease outbreaks; enterovirus.
INTRODUCTION: The prevelance of urinary system stone disease in children is emphasizing the need for minimally invasive treatments to decrease morbidity and recurrence risk. Percutaneous nephrolithotomy (PCNL) has emerged as a preferred approach for pediatric patients with complex stones due to its minimally invasive nature, including miniaturized and vacuum-assisted access sheaths, advanced laser technology and tubeless and outpatient procedures. However, adult scoring systems have proven ineffective in predicting success and complications in pediatric PCNL. This highlights the need for specialized scoring systems, such as the Stone-Kidney Size (SKS) scoring system, tailored to pediatric patients and will be evaluated in our study for its association with the stone-free rate (SFR) and complications.
MATERIALS AND METHODS: The data of 144 patients aged <17 years who had undergone PCNL between January 2008 and December 2019 were evaluated retrospectively. Demographics, stone characteristics, perioperative/postoperative outcomes were recorded for each patient. The SKS scoring system comprises the stone kidney index (SKI) and the number of stones, assigns one or two points based on single or multiple stones and an SKI value of <0.3 or ≥0.3, respectively. The SKI is computed by dividing the stone's longest axis by the kidney's longest axis. Residual stones less than 4 mm on non-contrast computed tomography are considered clinically insignificant residual fragments (CIRFs). Stone-free and CIRF patients were considered successful results. The relationship between the SKS scoring system and SFR, success, and complication rates after surgery was investigated. Statistical analyses were conducted using SPSS 22.0 software.
RESULTS: The SFR was 67.36% and 74.31% when CIRF patients were included, respectively, with a complication rate of 27%. In multivariate analysis, stone treatment history, stone burden, and SKS score were statistically significantly associated with SFR (p < 0.001, p = 0.032, p < 0.001, respectively). Furthermore, the SKS score was the only variable that showed a statistically significant relationship with success. No significant association was found between SKS score and complications (p = 0.342).
DISCUSSION: Our study demonstrates a relationship between the SKS scoring system and SFR in pediatric PCNL patients. However, shortcomings have been observed in its capacity to accurately predict post-PCNL complications. Despite being a retrospective analysis and having a single-center design, our study externally validates the relationship between the SKS scoring system and SFR after pediatric PCNL.
CONCLUSIONS: The SKS scoring system is associated with SFR in pediatric patients undergoing PCNL; however, this relationship has not been established for complications.
PURPOSE:To obtain a reviving agent enabling early revival of claws by dipping in a reaction product of serpentinite with sulfuric acid in water when animal claws are damaged. CONSTITUTION:Ninety-two kg serpentinite is charged into 59l water and 32kg of 98% sulfuric acid is added thereto. When the reaction system reaches boiling state, 35-40l cooling water is added thereto in a foaming state during 3-4min corresponding to the reactional foaming, in order to prevent overflowing of the reaction liquid out of device, and then stirring is continued for about 25min. Then, stirring is temporarily stopped and water is added thereto until the total water amount becomes 207l. The reaction liquid is stirred further for about 3min and allowed to stand for about 1hr. 130l of the reaction liquid is collected from the upper part to provide the objective reviving agent. Water is added to the remained liquid until the water amount reaches 97l and 26.6kg of 98% sulfuric acid is added thereto. When the liquid causes heat generation and becomes foaming state, 20-25l cooling water is added and the liquid is stirred for 25min. Stirring is temporarily stopped and water is added thereto until the total amount reaches 207l. The liquid is stirred for further 3min and the reaction liquid is recovered with residue of serpentinite while continuing stirring.
Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker If current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology (12.2)].

Corlanor can also inhibit the retinal current Ih. Ih is involved in curtailing retinal responses to bright light stimuli. Under triggering circumstances (e.g., rapid changes in luminosity), partial inhibition of Ih by Corlanor may underlie the luminous phenomena experienced by patients. Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field [see Adverse Reactions (6.1)].
SOLIRIS (eculizumab) injection is a sterile, preservative-free, clear, colorless solution supplied as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton (NDC 25682-001-01).

Store SOLIRIS vials refrigerated at 2°-8° C (36°-46° F) in the original carton to protect from light until time of use. SOLIRIS vials may be stored in the original carton at controlled room temperature (not more than 25° C/77° F) for only a single period up to 3 days. Do not use beyond the expiration date stamped on the carton. Refer to Dosage and Administration (2) for information on the stability and storage of diluted solutions of SOLIRIS.

DO NOT FREEZE. DO NOT SHAKE.